177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)

  1. Khreish, Fadi
  2. Ghazal, Zaidoon
  3. Marlowe, Robert J.
  4. Rosar, Florian
  5. Sabet, Amir
  6. Maus, Stephan
  7. Linxweiler, Johannes
  8. Bartholomä, Mark
  9. Ezziddin, Samer ORCID logo

Download
s00259-021-05525-7.pdf 794,76KB
WeightNameValue
1000 Titel
  • 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)
1000 Autor/in
  1. Khreish, Fadi |
  2. Ghazal, Zaidoon |
  3. Marlowe, Robert J. |
  4. Rosar, Florian |
  5. Sabet, Amir |
  6. Maus, Stephan |
  7. Linxweiler, Johannes |
  8. Bartholomä, Mark |
  9. Ezziddin, Samer |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-09-07
1000 Erschienen in
1000 Quellenangabe
  • 49(3):1075-1085
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00259-021-05525-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803625/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Preliminary data from retrospective analyses and recent data from large randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). Limited data on this modality have been published regarding large samples treated in everyday practice.!##!Methods!#!We analyzed prospectively collected registry data regarding lutetium-177 (!##!Results!#!Patients received 3 (1-13) !##!Conclusions!#!In a large, prospectively observed 'real-world' cohort with late-stage/end-stage mCRPC and conventional treatment failure,
1000 Sacherschließung
lokal Heterocyclic Compounds, 1-Ring/adverse effects [MeSH]
lokal Prostatic Neoplasms, Castration-Resistant/pathology [MeSH]
lokal Aged [MeSH]
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Prostate-Specific Antigen [MeSH]
lokal Treatment Outcome [MeSH]
lokal Retrospective Studies [MeSH]
lokal Everyday practice
lokal Lutetium/therapeutic use [MeSH]
lokal Original Article
lokal Metastatic castration-resistant prostate cancer (mCRPC)
lokal Lutetium-177-PSMA-617 radioligand therapy (
lokal Male [MeSH]
lokal “Real-world” data
lokal Dipeptides/adverse effects [MeSH]
lokal Radioisotopes [MeSH]
lokal Prostate-specific membrane antigen (PSMA)
lokal Registries [MeSH]
lokal Prostatic Neoplasms, Castration-Resistant/radiotherapy [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S2hyZWlzaCwgRmFkaQ==|https://frl.publisso.de/adhoc/uri/R2hhemFsLCBaYWlkb29u|https://frl.publisso.de/adhoc/uri/TWFybG93ZSwgUm9iZXJ0IEou|https://frl.publisso.de/adhoc/uri/Um9zYXIsIEZsb3JpYW4=|https://frl.publisso.de/adhoc/uri/U2FiZXQsIEFtaXI=|https://frl.publisso.de/adhoc/uri/TWF1cywgU3RlcGhhbg==|https://frl.publisso.de/adhoc/uri/TGlueHdlaWxlciwgSm9oYW5uZXM=|https://frl.publisso.de/adhoc/uri/QmFydGhvbG9tw6QsIE1hcms=|https://orcid.org/0000-0003-4110-3375
1000 Hinweis
  • DeepGreen-ID: 73b13dc3d05b483186aae780458032d8 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6451485.rdf
1000 Erstellt am 2023-05-11T13:41:38.546+0200
1000 Erstellt von 322
1000 beschreibt frl:6451485
1000 Zuletzt bearbeitet 2023-10-23T15:49:06.178+0200
1000 Objekt bearb. Mon Oct 23 15:49:06 CEST 2023
1000 Vgl. frl:6451485
1000 Oai Id
  1. oai:frl.publisso.de:frl:6451485 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source